Aprea AB announces efficacy and safety data in high-grade serous ovarian cancer patients treated with investigational APR-246 presented at 2016 ASCO Annual Meeting

By | | No Comments
June 6, 2016—Aprea AB, a privately held, clinical-stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial in collaboration with the European Network for Translational Research in Ovarian Cancer (EUTROC).
Read More